In vitro activity of a novel broad-spectrum antifungal, e1210, tested against candida spp. as determined by clsi broth microdilution method

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 2, 2011, Pages 167-170

  Pfaller, Michael A ^a   Hata, Katsura ^b   Jones, Ronald N ^a,c   Messer, Shawn A ^a   Moet, Gary J ^a   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b Tufts University School of Medicine ^*

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Candida; E1210; GPI inhibitor; Resistance

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; E 1210; FLUCONAZOLE; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DRUG POTENCY; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 80052857736     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.05.001     Document Type: Article

References (15)

1. Castanheira M., Woosley L.N., Pfaller M.A., Diekema D.J., Messer S.A., Jones R.N. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp. Antimicrob. Agents Chemother. 2010, 54:2655-2659.
2. Chen S.C., Playford E.G., Sorrell T.C. Antifungal therapy in invasive fungal infections. Curr. Opin. Pharmacol. 2010, 10:522-530.
3. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts 2008, CLSI, Wayne, PA. 3rd ed, M27-A3.
4. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd informational supplement, (M27-S3) 2008, CLSI, Wayne, PA.
5. Fridkin S.K. The changing face of fungal infections in health care settings. Clin. Infect. Dis. 2005, 41:1455-1460.
6. Miyazaki M., Horii T., Hata K., Watanabe M. In vitro antifungal activity of E1210: A novel antifungal with activity against clinically important yeasts and moulds 2010.
7. Pfaller M.A., Andes D., Diekema D.J., Espinel-Ingroff A., Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 2010, 13:180-195. The Subcommittee for Antifungal Susceptibility Testing.
8. Pfaller M.A., Castanheira M., Diekema D.J., Messer S.A., Moet G.J., Jones R.N. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J. Clin. Microbiol. 2010, 48:1592-1599.
9. Pfaller M.A., Castanheira M., Messer S.A., Moet G.J., Jones R.N. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn. Microbiol. Infect. Dis. 2010, 68:278-283.
10. Pfaller M.A., Diekema D.J., Andes D., Arendrup M.C., Brown S.D., Motyl M., Perlin D.S. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 2010, The Subcommittee for Antifungal Susceptibility Testing, (in press).
11. Sipsas N.V., Lewis R.E., Tarrand J., Hachem R., Rolston K.V., Raad I.I., Kontoyiannis D.P. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009, 115:4745-4752.
12. Spellberg B.J., Filler S.G., Edwards J.E. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 2006, 42:244-251.
13. Tsukahara K., Hata K., Nakamoto K., Sagane K., Watanabe N.A., Kuromitsu J., Kai J., Tsuchiya M., Ohba F., Jigami Y., Yoshimatsu K., Nagasu T. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly. Mol. Microbiol. 2003, 48:1029-1042.
14. Umemura M., Okamoto M., Nakayama K., Sagane K., Tsukahara K., Hata K., Jigami Y. GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast. J. Biol. Chem. 2003, 278:23639-23647.
15. Watanabe N., Horii T., Miyazaki M., Hata K. E1210, a new broad-spectrum antifungal, inhibits glycosylphosphatidylinositl (GPI) biosynthesis and effects Candida albicans cell characteristics 2010.